A small French-US biotech has gathered more funds to see if it can follow in the footsteps of Krystal Biotech in the HSV-based gene therapy field, but in a different therapeutic area. Cyllene Therapeutics raised …
Source: Endpoints News
You may also like
Cancer, immune drugmakers dominate VC funding so far...
Beyond Boston: Unlikely cities stake biotech claims
Vera Therapeutics wins FDA nod for closely watched...
Gene editing developer Scribe plots an IPO
Novartis to acquire ADC developer in a deal worth up...
Novartis to pay $1.1B upfront for UK biotech Myricx to...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.